Catabasis Pharmaceuticals, Inc. (CATB)
Stock Price:
$6.70 USD
0.09 (1.36%)
Updated Aug 12, 2020 10:29 AM EDT - Market open
Key Info
| Market Cap |
127.84M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-30.58M |
| Shares Out |
19.08M |
| EPS (ttm) |
-2.21 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 12, 2020 |
| Last Price |
$6.70 |
| Previous Close |
$6.61 |
| Change ($) |
0.09 |
| Change (%) |
1.36% |
| Day's Open |
6.65 |
| Day's Range |
6.54 - 6.82 |
| Day's Volume |
30,145 |
| 52-Week Range |
2.74 - 7.73 |
More Stats
| Market Cap |
127.84M |
| Enterprise Value |
75.32M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
19.08M |
| Float |
16.95M |
| EPS (basic) |
-2.14 |
| EPS (diluted) |
-2.21 |
| FCF / Share |
-1.60 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
763,029 |
| Short Ratio |
4.96 |
| Short % of Float |
4.90% |
| Beta |
1.69 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
2.21 |
| Revenue |
n/a |
| Operating Income |
-31.02M |
| Net Income |
-30.58M |
| Free Cash Flow |
-28.73M |
| Net Cash |
52.52M |
| Net Cash / Share |
2.75 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-31.67% |
| ROE |
-54.46% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$37.50*
(459.70% upside)
Low
15.0
Current: $6.70
High
60.0
Target: 37.50
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | - | - | 0.50 | - | - | - | - |
| Gross Profit | - | - | 0.50 | - | - | - | - |
| Operating Income | -27.09 | -26.37 | -27.09 | -35.56 | -31.66 | -21.68 | -18.12 |
| Net Income | -26.29 | -25.87 | -27.36 | -36.06 | -32.63 | -21.88 | -18.12 |
| Shares Outstanding | 11.20 | 5.05 | 2.17 | 1.62 | 0.80 | 0.04 | 0.04 |
| Earnings Per Share | -2.35 | -5.12 | -12.62 | -22.20 | -40.60 | -515.60 | -478.00 |
| Operating Cash Flow | -26.57 | -23.47 | -26.84 | -32.86 | -29.79 | -20.41 | -16.37 |
| Capital Expenditures | -0.01 | 0.37 | -0.03 | -0.41 | -0.42 | -0.23 | -0.04 |
| Free Cash Flow | -26.58 | -23.10 | -26.86 | -33.27 | -30.21 | -20.64 | -16.41 |
| Cash & Equivalents | 36.24 | 37.57 | 16.48 | 38.64 | 62.89 | 14.78 | 30.59 |
| Total Debt | 2.25 | - | 2.48 | 5.72 | 8.89 | 4.75 | - |
| Net Cash / Debt | 33.99 | 37.57 | 14.00 | 32.92 | 54.00 | 10.03 | 30.59 |
| Assets | 41.78 | 39.17 | 17.90 | 40.21 | 64.17 | 15.96 | 31.00 |
| Liabilities | 6.06 | 4.23 | 6.11 | 11.12 | 13.68 | 8.87 | 83.19 |
| Book Value | 35.72 | 34.94 | 11.79 | 29.09 | 50.49 | -73.05 | -52.18 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Catabasis Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
27 |
| CEO |
Jill C. Milne |
Stock Information
| Ticker Symbol |
CATB |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CATB |
| IPO Date |
June 25, 2015 |
Description
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activate B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). It is also involved in developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a pre-clinical joint research collaboration agreement with Sarepta Therapeutics, Inc. to explore a combination drug treatment approach for DMD; and collaboration with the University of Texas Southwestern to study the potential benefits of edasalonexent treatment. The company also has a preclinical research collaboration with the Jain Foundation to study edasalonexent (CAT-1004) in Dysferlinopathy. The company was founded in 2008 and is based in Cambridge, Massachusetts.